Robinson Smith Wealth Advisors LLC Invests $205,000 in IDEXX Laboratories, Inc. $IDXX

Robinson Smith Wealth Advisors LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 383 shares of the company’s stock, valued at approximately $205,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Moors & Cabot Inc. acquired a new position in IDEXX Laboratories in the second quarter valued at approximately $228,000. Blue Barn Wealth LLC acquired a new position in IDEXX Laboratories in the second quarter valued at approximately $225,000. Ellevest Inc. boosted its holdings in IDEXX Laboratories by 2.1% in the second quarter. Ellevest Inc. now owns 1,143 shares of the company’s stock valued at $613,000 after purchasing an additional 24 shares in the last quarter. Crestwood Advisors Group LLC boosted its holdings in IDEXX Laboratories by 3.7% in the second quarter. Crestwood Advisors Group LLC now owns 860 shares of the company’s stock valued at $461,000 after purchasing an additional 31 shares in the last quarter. Finally, Jacobson & Schmitt Advisors LLC boosted its holdings in IDEXX Laboratories by 7.7% in the second quarter. Jacobson & Schmitt Advisors LLC now owns 26,899 shares of the company’s stock valued at $14,427,000 after purchasing an additional 1,912 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDXX has been the subject of a number of research analyst reports. UBS Group upped their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a report on Tuesday. JPMorgan Chase & Co. upped their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research note on Monday. Morgan Stanley boosted their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $730.50.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $722.12 on Wednesday. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $735.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The business has a 50 day simple moving average of $641.13 and a 200-day simple moving average of $574.15. The stock has a market capitalization of $57.77 billion, a PE ratio of 60.13, a price-to-earnings-growth ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, November 3rd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.14 by $0.26. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the business earned $2.80 earnings per share. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 2,187 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the sale, the director owned 262 shares in the company, valued at $169,600.46. This represents a 89.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael G. Erickson sold 406 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the sale, the executive vice president owned 11,287 shares of the company’s stock, valued at $7,336,098.52. This trade represents a 3.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 9,243 shares of company stock worth $6,018,650 over the last three months. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.